Clinical Trials Logo

Clinical Trial Summary

Survival of intermediate and high-risk primary light chain amyloidosis (pAL) remains poor due to high mortality within 3-6 months of diagnosis. Rapidly effective regimens such as bortezomib, cyclophosphamide and dexamethasone (BCD) still failed to overcome the poor prognosis in very advanced pAL amyloidosis patients. Recently, doxycycline was demonstrated to induce disruption of fibril formation and reduce the number of intact fibrils in transgenic mouse model of pAL amyloidosis. Furthermore, case-control study suggested that adjuvant oral doxycycline could improve response and survival in cardiac pAL amyloidosis, which necessities further confirmation through a randomized trial. Therefore, we designed a multi-center randomized open-label controlled study to investigate the efficacy and safety of co-administration of oral doxycycline with BCD regimen in treatment-naïve patients with Mayo stage II-III pAL amyloidosis. The primary outcome progression-free survival, and secondary endpoints including overall survival, hematologic response, organ response and toxicity of doxycycline will be evaluated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03401372
Study type Interventional
Source Peking Union Medical College Hospital
Contact
Status Completed
Phase N/A
Start date April 21, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05951049 - A Study of AT-02 in Subjects With Systemic Amyloidosis. Phase 2
Recruiting NCT05521022 - Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis Phase 1
Completed NCT05201911 - A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis Phase 1
Active, not recruiting NCT04474938 - Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis Phase 2
Terminated NCT02994784 - Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Phase 2
Recruiting NCT06192979 - Optimize First-line Treatment for AL Amyloidosis With t (11; 14) N/A